Cargando…

Valproate-Induced Hyperammonemic Encephalopathy

Valproate is the best choice drug for a variety of medical conditions. As with any other drug, it has adverse effects, and it is important to emphasize the possibility of those adverse effects to prevent complications. We present the case history of a 44-year-old male with valproate-induced hyperamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Farooq, Faiza, Sahib Din, Javeria, Khan, Ali M, Naqvi, Syeda, Shagufta, Shanila, Mohit, Abdul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650254/
https://www.ncbi.nlm.nih.gov/pubmed/29062625
http://dx.doi.org/10.7759/cureus.1593
_version_ 1783272668127035392
author Farooq, Faiza
Sahib Din, Javeria
Khan, Ali M
Naqvi, Syeda
Shagufta, Shanila
Mohit, Abdul
author_facet Farooq, Faiza
Sahib Din, Javeria
Khan, Ali M
Naqvi, Syeda
Shagufta, Shanila
Mohit, Abdul
author_sort Farooq, Faiza
collection PubMed
description Valproate is the best choice drug for a variety of medical conditions. As with any other drug, it has adverse effects, and it is important to emphasize the possibility of those adverse effects to prevent complications. We present the case history of a 44-year-old male with valproate-induced hyperammonemic encephalopathy, despite having normal liver function tests. This case includes a detailed literature review of this rare adverse event. In the light of this case report, we illustrate the importance of checking ammonia levels in all psychiatric patients receiving valproate as a treatment who present with new onset neurological symptoms or altered mental status.
format Online
Article
Text
id pubmed-5650254
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-56502542017-10-23 Valproate-Induced Hyperammonemic Encephalopathy Farooq, Faiza Sahib Din, Javeria Khan, Ali M Naqvi, Syeda Shagufta, Shanila Mohit, Abdul Cureus Psychiatry Valproate is the best choice drug for a variety of medical conditions. As with any other drug, it has adverse effects, and it is important to emphasize the possibility of those adverse effects to prevent complications. We present the case history of a 44-year-old male with valproate-induced hyperammonemic encephalopathy, despite having normal liver function tests. This case includes a detailed literature review of this rare adverse event. In the light of this case report, we illustrate the importance of checking ammonia levels in all psychiatric patients receiving valproate as a treatment who present with new onset neurological symptoms or altered mental status. Cureus 2017-08-22 /pmc/articles/PMC5650254/ /pubmed/29062625 http://dx.doi.org/10.7759/cureus.1593 Text en Copyright © 2017, Farooq et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Psychiatry
Farooq, Faiza
Sahib Din, Javeria
Khan, Ali M
Naqvi, Syeda
Shagufta, Shanila
Mohit, Abdul
Valproate-Induced Hyperammonemic Encephalopathy
title Valproate-Induced Hyperammonemic Encephalopathy
title_full Valproate-Induced Hyperammonemic Encephalopathy
title_fullStr Valproate-Induced Hyperammonemic Encephalopathy
title_full_unstemmed Valproate-Induced Hyperammonemic Encephalopathy
title_short Valproate-Induced Hyperammonemic Encephalopathy
title_sort valproate-induced hyperammonemic encephalopathy
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650254/
https://www.ncbi.nlm.nih.gov/pubmed/29062625
http://dx.doi.org/10.7759/cureus.1593
work_keys_str_mv AT farooqfaiza valproateinducedhyperammonemicencephalopathy
AT sahibdinjaveria valproateinducedhyperammonemicencephalopathy
AT khanalim valproateinducedhyperammonemicencephalopathy
AT naqvisyeda valproateinducedhyperammonemicencephalopathy
AT shaguftashanila valproateinducedhyperammonemicencephalopathy
AT mohitabdul valproateinducedhyperammonemicencephalopathy